Top Myeloma Research Presented at ASH 2025

Key Highlights from ASH 2025 – Myeloma Updates

0:00:00 Event Overview:
ASH (American Society of Hematology) hosted its largest annual meeting with over 9,000 abstracts submitted, including 1,500+ related to multiple myeloma.
Attendance: 27,500 in-person and 3,500 virtual participants.

0:07:58 Top 10 Abstracts:
0:09:30 CAR T Cell Therapy (5 abstracts)
0:09:43 - In vivo CAR T (LBA-1) – novel gene therapy approach.
0:14:07 - Long-term follow-up of cilta-cel shows sustained progression-free survival.
0:18:28 - Safety enhancements for cilta-cel to reduce neurotoxicity.
0:21:27 - Dual-target FasTCAR-T for frontline therapy.
0:23:22 - Anito-cel (D-domain CAR T) demonstrates deep responses and manageable safety.

0:25:31 CAR T Cell Therapy Insights
Most effective therapy for multiple myeloma with remarkable long-term outcomes.
Novel approaches include:In vivo CAR T delivery (simplifies logistics, reduces cost).
Dual-targeting CAR T for deeper responses.
D-domain CAR T for improved safety and efficiency.
Key considerations:Effective bridging therapy reduces toxicity.
Earlier use in standard-risk patients improves survival.

0:39:21 Bispecific Antibodies (5 abstracts)
0:39:37 - Teclistamab + Daratumumab in early relapse
0:43:40 - Teclistamab + Daratumumab frontline settings.
0:45:41 - Linvoseltamab for MRD-positive patients post-induction.
0:50:12 - Cevostamab consolidation after CAR T therapy.
0:52:01 - Teclistamab + Talquetamab for aggressive extramedullary disease.
0:54:15 - Elranatamab + Iberdomide combination shows high ORR.

0:55:33 Bispecific Antibody Advances
Potent combinations (e.g., Teclistamab + Daratumumab) in both frontline and relapse settings.
Fixed-duration strategies (Linvoseltamab, Cevostamab) post-CAR T therapy.
Dual bispecific combinations (Teclistamab + Talquetamab) highly effective in aggressive disease.
Integration with CelMods for enhanced efficacy.

1:04:52 Future Directions in Myeloma Therapy
Continued evolution toward:Novel CAR T platforms (dual-target, in vivo).
Bispecific/Trispecific antibodies.
Next-gen immunomodulators (Iberdomide, Mezigdomide).
Targeted small molecules for specific genetic subtypes.

Patient-Centered Questions:
Should CAR T move to earlier lines for standard-risk patients?
How to manage infection risk with bispecific antibodies?
Is fixed-duration therapy the future for bispecifics?
Will dual bispecific combinations become standard?


_______________
Improving Lives | Finding the Cure

Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.

Subscribe to our channel:    / imfmyeloma  

Visit our website at: https://www.myeloma.org

Find us online:
Facebook: @myeloma |   / myeloma  
X/Twitter: @IMFMyeloma |   / imfmyeloma  
Instagram: @imfmyeloma |   / imfmyeloma  
LinkedIn:   / international-myeloma-foundation  

Support the IMF | Donate Now! https://fundraise.myeloma.org/give/52...

Category
Nonprofits & Activism
License
Standard YouTube License

The International Myeloma Foundation is committed to accessibility for all. That’s why all English-language videos uploaded to our YouTube channel feature human-transcribed closed captioning. This ensures more accurate captions for viewers who are Deaf or hard of hearing and improves the quality of automatic translations into other languages for our global audience.